Insulin Mimotope Enhances T Cell Detection Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively identifying and monitoring T cell responses associated with Type 1 diabetes (T1D), which hinders the development of personalized therapies and disease progression monitoring.
Innovation Solution
The use of a modified insulin B chain peptide mimotope with a B22 Arg→Glu mutation, which enhances binding to specific MHC class II molecules, allowing for improved detection of diabetogenic T cells and induction of tolerance, is proposed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If wild type insulin B:9-23 peptide is used for detection, then the method is simple and uses native antigen, but the detection sensitivity is low due to poor binding to MHC class II molecules
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the insulin B:9-23 peptide, specifically changing the binding register and substituting B22 Arg with Glu to enhance MHC class II binding affinity. This chemical parameter modification transforms the peptide from poor binder to high-affinity binder, resolving the contradiction between using native antigen simplicity and achieving detection sensitivity.
Solution Approach 2:
The patent creates a mimotope - a modified peptide copy of the original insulin B:9-23 epitope that replicates the antigenic properties while improving MHC binding. The mimotope serves as an optimized copy that maintains immunological relevance while overcoming the binding deficiency of the wild type peptide, enabling sensitive detection without requiring the native peptide's limitations.
2Measurement precision
If modified insulin mimotope is used to enhance T cell detection, then detection sensitivity improves, but the method complexity increases
Solution Approach 1:
The patent modifies physical-chemical parameters of the peptide (amino acid substitution, binding register) to create a mimotope that enhances T cell detection sensitivity approximately 100-fold. This parameter optimization allows the assay to detect low-frequency diabetogenic T cells that would be undetectable with wild type peptide, while the modified peptide itself remains a simple molecular entity.
3Ease of operation
If insulin preparations are used to induce tolerance, then therapeutic intervention is provided, but monitoring of T cell response remains challenging
Solution Approach 1:
The patent creates a detection-specific mimotope copy of the insulin epitope that is optimized for T cell recognition and assay detection. This copied peptide structure enables sensitive monitoring of T cell responses to insulin, providing a tool to assess whether tolerance-inducing therapies are successfully converting pathogenic T cell responses to regulatory responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables robust detection of inflammatory T cell responses in T1D patients and potentially prevents diabetes onset by stimulating regulatory responses, as demonstrated in the nonobese diabetic mouse model and human subjects.
Implementation Method 1
insulin B chain amino acids 9-23 (B:9-23), a key epitope presented by major histocompatibility (MHC) class II molecules to CD4 T cells
Implementation Method 2
The binding of the peptide in this register can be greatly enhanced by creating a mimotope with mutation of B22 Arg→Glu, which now places the highly favorable acidic Glu in the p9 pocket. This peptide mimotope stimulates B:9-23 specific CD4 T cells about 100-fold better than the wild type peptide
Implementation Method 3
potentially prevents diabetes onset by stimulating regulatory responses, as demonstrated in the nonobese diabetic mouse model and human subjects
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that induces conversion of naive T cells into Foxp3+ regulatory T cells to induce immunosuppression in the subject. Methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease, particularly type 1 diabetes.